The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
Recent Posts
- Pudgy Penguins Launches Visa-Backed Crypto Debit Card Worldwide — PENGU Spikes Nearly 5.6%
- Bitcoin Doesn’t Face ‘Existential’ Risk From Quantum Computers, Says Brian Armstrong: ‘With Good Work, We Can Make Sure That Lands In A Good Place’
- 6:1 Rights Issue: Textile stock rises 11% after it sets record date for ₹42 Cr Rights Issue
- Defence Stock Jumps 15% After Receiving ₹460 Cr Order for Satellite Communication Equipment
- Why Did PG Electroplast Shares Jump 9% Today? Here’s the Reason